iRxReminder LLC, a health technology company, is pleased to announce that it has received an NIH Award for its patented technology and approach to improving patient outcomes in the treatment of Tardive Dyskinesia (TD), a movement disorder characterized by uncontrollable, abnormal, and repetitive movements, which can affect up to 6 million people in the US. There is no cure for TD, and the cost of treatment is significant and can exceed $50,000 per patient per year.
research partner of iRxReminder; — Provo, UT-based Videra Health, New York City-based Fermata Health, and Cleveland, OH-based Charak Health and Wellness will join to validate the use of artificial intelligence with telemedicine for early disease detection, allowing for more timely clinical intervention. iRxReminder’s patented technology is also designed to help TD patients adhere to their antipsychotic medications by providing reminders and tracking tools that further help prevent costly adverse events or unexpected crisis activities, leading to improved patient outcomes with reduced care costs.
“We are honored to receive this grant from the NIH and excited about the potential of our platform to improve the lives of patients with tardive dyskinesia,” said Anthony Sterns, Ph.D., CEO of iRxReminder. “We believe our medication monitoring and management technology can play a critical role in helping patients adhere to their treatment plans, which is essential to managing the symptoms of this debilitating condition.”
Owen Muir, M.D., Dual Board-Certified (Child and Adult) Psychiatrist, CMO of iRxReminder, also commented, “Increasingly, antipsychotic medications are being used in addition to conditions such as schizophrenia and bipolar disorder as an exacerbation of conditions such as depression. This technology allows us to bring early detection, screening, and intervention for TD to more patients.”
The grant includes a number of national and local technology partners and consultants, including Dr. Joel Hughes and Brown University from the Department of Psychology at Kent State University and Dr. Joel Friedman of Butler Hospital. The NIH SBIR program provides funds to small companies to support the research and development of innovative technologies that have the potential for commercialization and public benefit. The iRxReminder grant is part of the program’s effort to support research into the treatment of rare diseases.
